"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
38, NCT04371276, Seroepidemiology of Viral Hepatitis in Hong Kong, , Enrolling by invitation, No Results Available, Viral Hepatitis, Other: No intervention, hepatitis B infection prevalence|hepatitis A immunity prevalence, Chinese University of Hong Kong, All, Child, Adult, Older Adult, , 3981, Other, Observational, Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional, 17160962, September 1, 2018, July 31, 2021, May 31, 2022, May 1, 2020, , January 27, 2021, Prince of Wales Hospital, Hong Kong, Hong Kong, China, , https://ClinicalTrials.gov/show/NCT04371276
45, NCT00186836, Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients, , Completed, No Results Available, Hepatitis B, Biological: Engerix-B and Twinrix, Hepatitis B antibody response at month 7 (Significant antibody response defined as anti-HBs Ab greater than or equal to 10mIU/mL ).|Anti-HBs geometric mean response at 7 months.|Efficacy of Twinrix® in achieving seroprotection against HAV in hemodialysis patients(Significant antibody response defined as at least 20mIU/mL concentration of anti-HAV.)|Frequency of adverse events associated with vaccine administration, St. Joseph's Health Care London|St. Joseph's Healthcare Hamilton, All, 18 Years and older   (Adult, Older Adult), Phase 4, 200, Other, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention, 2400, November 2004, , November 2006, September 16, 2005, , April 20, 2007, St. Joseph's Healthcare, Hamilton, Ontario, Canada, , https://ClinicalTrials.gov/show/NCT00186836
52, NCT01126853, Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders, , Withdrawn, No Results Available, Hepatitis B, Biological: Twinrix, Protective immunity to Hepatitis B|Adverse Events|Rate of Recruitment|Partial immunity to Hepatitis B, Mount Sinai Hospital, Canada|University of Toronto, All, 18 Years to 69 Years   (Adult, Older Adult), Phase 4, 0, Other, Interventional, Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, MSH 09-0220-E|R09-15, April 2010, June 2011, July 2011, May 20, 2010, , June 1, 2020, Mount Sinai Hospital, Toronto, Ontario, Canada, , https://ClinicalTrials.gov/show/NCT01126853
76, NCT01159951, Analysis of Trends Over Time of Hepatitis Related Incidence in Panama, , Completed, No Results Available, Hepatitis, Other: Epidemiologic Surveillance System of the Ministry of Health of Panama, Occurrence of reported hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis)|Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by year|Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by age groups|Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by region, GlaxoSmithKline, All, Child, Adult, Older Adult, , 1, Industry, Observational, Observational Model: Other|Time Perspective: Retrospective, 112263, January 2009, August 2011, August 2011, July 12, 2010, , June 7, 2017, GSK Investigational Site, Clayton, Panamá, Panama, , https://ClinicalTrials.gov/show/NCT01159951
79, NCT01912404, Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy, AH, Terminated, Has Results, Alcoholic Hepatitis, Drug: IDN-6556|Drug: Placebo, Survival, Conatus Pharmaceuticals Inc.|National Institute on Alcohol Abuse and Alcoholism (NIAAA), All, 21 Years and older   (Adult, Older Adult), Phase 2, 5, Industry|NIH, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment, IDN-6556-04|5U01AA021788, July 2013, August 2015, August 2015, July 31, 2013, November 4, 2016, November 4, 2016, Indiana University, Indianapolis, Indiana, United States|Mayo Clinic, Rochester, Minnesota, United States|Virginia Commonwealth University, Richmond, Virginia, United States, , https://ClinicalTrials.gov/show/NCT01912404
91, NCT04600479, Study on the Prevalence of Hepatitis C In a psychiatRic Population, SaPHIR, Recruiting, No Results Available, Hepatitis C, Diagnostic Test: Evaluation of the prevalence of HCV, HBV and HIV viral infections, Estimation of the prevalence of chronic hepatitis C in a psychiatric population|Effectiveness of the care pathway of the HCV-infected patient|Prevalence of hepatitis C in a psychiatric population (cured hepatitis and chronic active hepatitis)|Prevalence of active hepatitis B in a psychiatric population|Prevalence of HIV in a psychiatric population|Prevalence of HCV-HBV-HIV co-infections in a psychiatric population|Prevalence of hepatitis C in the sub-population of IDU patients, Nantes University Hospital, All, 15 Years and older   (Child, Adult, Older Adult), Not Applicable, 796, Other, Interventional, Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other, RC20_0022, November 26, 2020, August 26, 2023, August 26, 2023, October 23, 2020, , December 1, 2020, CHU Nantes, Nantes, France, , https://ClinicalTrials.gov/show/NCT04600479
103, NCT00412763, Efficacy of Silymarin for Acute Hepatitis, , Completed, No Results Available, Hepatitis, Drug: Silymarin (Silybum marianum), Primary outcomes were symptoms and signs of acute hepatitis and results of liver function tests on days 3, 5 and 7 in the hospital and in the outpatient clinic at weeks 2, 4, and 8.|Side-effects and adverse events were ascertained by self-report on days 3, 5 and 7 in the hospital and in the outpatient clinic at weeks 2, 4, and 8. ., University of Maryland, College Park|University of Maryland, Baltimore, All, 13 Years to 70 Years   (Child, Adult, Older Adult), Phase 4, 200, Other, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment, H-21829, July 2003, , October 2005, December 18, 2006, , December 18, 2006, , , https://ClinicalTrials.gov/show/NCT00412763
172, NCT03149874, Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients, , Completed, No Results Available, Hepatitis B|Hemodialysis Complication, Drug: Hepatitis B Vaccines, Hepatitis B virus Seroprotection after one month|Hepatitis B virus Seroprotection after three months|Fever|Pain scale, Benha University|New Jeddah Clinic Hospital, All, 19 Years and older   (Adult, Older Adult), Not Applicable, 114, Other|Industry, Interventional, Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, BN-0517, December 1, 2014, April 30, 2017, May 1, 2017, May 11, 2017, , May 11, 2017, , , https://ClinicalTrials.gov/show/NCT03149874
191, NCT01768715, Liver Transplantation in Alcoholic Hepatitis, SETH-HA, Suspended, No Results Available, Alcoholic Hepatitis, , Evaluate survival of patients with severe alcoholic hepatitis non responsive to therapy after liver transplantation|Evaluate the applicability of liver transplantation in patients with alcoholic hepatitis non responsive to steroid therapy|Evaluate the mortality in waiting list for transplantation of patients with alcoholic hepatitis unresponsive to steroid therapy|Evaluate the rate of alcohol recidivism after liver transplantation for alcoholic hepatitis|Evaluate survival of patients with alcoholic hepatitis after liver transplantation., Sociedad Española de Trasplante Hepático|Fundación Mutua Madrileña, All, 18 Years to 65 Years   (Adult, Older Adult), , 40, Other, Observational, Observational Model: Case-Control|Time Perspective: Prospective, SETH-HA, January 2013, December 2014, December 2017, January 15, 2013, , June 3, 2014, Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Clínico Universitario de Santiago, Santiago de Compostela, La Coruña, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Virgen de la Nieves, Granada, Spain|Complejo Hospitalario Universitario de la Coruña, La Coruña, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital La Fe, Valencia, Spain|Hospital Río Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain, , https://ClinicalTrials.gov/show/NCT01768715
257, NCT01102296, Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection, , Completed, No Results Available, Hepatitis, Biological: Hepatitis A vaccine, the proportion of vaccinees who achieve anti-HAV antibody concentrations of 20 mIU/ml or greater at week 48 of vaccination|the concentrations of anti-HAV antibody at week 48 of vaccination, National Taiwan University Hospital, Male, 18 Years to 40 Years   (Adult), Not Applicable, 582, Other, Interventional, Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, 200903063M, June 2009, March 2012, April 2012, April 13, 2010, , December 27, 2012, National Taiwan University Hospital, Taipei, Taiwan, , https://ClinicalTrials.gov/show/NCT01102296
269, NCT01980745, CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS, , Completed, No Results Available, Hepatitis, Autoimmune, Drug: Chloroquine diphosphate 250mg|Drug: Placebo, Recurrence of autoimune hepatitis after treatment withdrawal in patients maintained only with chloroquine|Side effects of chloroquine, University of Sao Paulo General Hospital, All, 18 Years to 70 Years   (Adult, Older Adult), Phase 4, 61, Other, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment, CAPPesq 0697/07|0697/07, February 2002, November 2013, June 2015, November 11, 2013, , October 26, 2016, University of São Paulo School of Medicine, Sao Paulo, Brazil, , https://ClinicalTrials.gov/show/NCT01980745
654, NCT02015403, To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed, , Completed, No Results Available, Ischemic Hepatitis, Drug: Standard Care + NAC (N -ACETYLCYSTEINE)|Drug: Standard Care (in control arm), To study the efficacy of NAC (N -ACETYLCYSTEINE) in preventing ischemic hepatitis in cirrhotics with upper Gastrointestinal bleed.|To study effect of NAC (N -ACETYLCYSTEINE) infusion on 5 day survival post bleed.|To study incidence of complication like AKI (Acute Kidney Injury), HE(Hepatic Encepahlopathy) and SBP(Spontaneous Bacterial Peritonitis)., Institute of Liver and Biliary Sciences, India, All, 18 Years to 75 Years   (Adult, Older Adult), Not Applicable, 220, Other, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment, ILBS-IH-01, December 2013, May 2015, May 2015, December 19, 2013, , September 13, 2019, Institute of Liver & Biliary Sciences, New Delhi, Delhi, India, , https://ClinicalTrials.gov/show/NCT02015403
760, NCT00197158, Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response, , Completed, No Results Available, Hepatitis B, Biological: Hepatitis B vaccine, Measurement of antibody concentrations to hepatitis B antigen at Month 7.|Measurement of antibody concentrations to hepatitis antigen at Months 1,2and6. Occurrence of solicited local symptoms and solicited general symptoms during the 4-day f/u period after vaccination. Occurrence, intensity and relationship to vaccination, GlaxoSmithKline, All, 18 Years and older   (Adult, Older Adult), Phase 4, 280, Industry, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention, 104387, March 2005, December 2005, December 2005, September 20, 2005, , September 21, 2016, GSK Investigational Site, Wilrijk, Belgium, , https://ClinicalTrials.gov/show/NCT00197158
866, NCT03439488, A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B, , Completed, No Results Available, Chronic Hepatitis B, Drug: JNJ-440|Drug: Placebo, Parts 1, 2, and 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability|Parts 1, 2, and 3: Number of Participants With Clinically Significant Changes in Physical Examination (Body Weight Measurement and Skin Examination)|Parts 1, 2, and 3: Number of Participants With Clinically Significant Changes in Vital Signs|Parts 1, 2, and 3: Number of Participants With ECG Abnormalities|Parts 1, 2, and 3: Number of Participants With Holter Monitoring Abnormalities|Parts 1, 2, and 3: Number of Participants With Clinical Laboratory Abnormalities|Part 1: Maximum Observed Plasma Concentration (Cmax)|Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])|Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])|Part 3: Maximum Observed Plasma Concentration (Cmax)|Part 3: Observed Plasma Concentration From Time 0 to tau Hours Postdose (C[0-tau])|Part 3: Area Under the Curve From Time Zero to End of Dosing Interval (AUC[0-tau])|Part 1: Ratio of Cmax Values Between Test and Reference Ratio (Cmax, test/reference) for Different Dosage Forms|Part 1: Ratio of AUC(0-last) Values Between Test and Reference (Ratio AUC[0-last],test/reference) for Different Dosage Forms|Part 1: Ratio of AUC(0-infinity) Values Between Test and Reference (Ratio AUC[0-infinity], test/reference) for Different Dosage Forms|Part 1: Ratio of Cmax Values Between Fed and Fasted (Ratio Cmax, test/reference) Conditions|Part 1: Ratio of AUC(0-last) Values Between Fed and Fasted (Ratio AUC[0- last],test/reference)|Part 1: Ratio of AUC(0-infinity) Values Between Fed and Fasted (Ratio AUC[0-infinity], test/reference)|Part 3: Mean Change from Baseline in HBV DNA Levels|Part 3: Percentage of Participants with HBV DNA Levels and Undetectable HBV DNA|Part 3: Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels|Part 3: Change From Baseline in Hepatitis B e Antigen (HBeAg) Levels|Part 3: Relationship Between Plasma Concentration and Antiviral Activity|Part 3: Relationship Between Plasma Concentration and Select AEs or Laboratory Changes|Part 3: Change From Baseline in HBV DNA (Antiviral Activity) in Chronic Hepatitis B (CHB) Participants with Sequence Variations in the HBV Genome|Part 3: Number of Participants with Emergence of Treatment Associated Mutations in the HBV Genome|Parts 1, 2, and 3: Relationship Between JNJ-440 Plasma Concentrations and Time-Matched Change from Baseline QTcF, Alios Biopharma Inc., All, 18 Years to 55 Years   (Adult), Phase 1, 130, Industry, Interventional, Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other, JNJ-440-1301|2017-004657-17, March 26, 2018, October 10, 2019, October 10, 2019, February 20, 2018, , December 10, 2019, Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Republican Clinical Hospital, Chisnau, Moldova, Republic of|Auckland Clinical Services, Auckland, New Zealand|Research Unit of Hepatitis and Liver Cancer, Department.Biochemistry, Faculty of Medicine King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Srinagarind Hospital Department of Gastroenterology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand|Limited Liability Company "ARENSIA EXPLORATORY MEDICINE", Kapitanavka, Ukraine, , https://ClinicalTrials.gov/show/NCT03439488
1635, NCT00608192, HIV and Hepatitis Care Coordination in Methadone Treatment, , Completed, No Results Available, Hepatitis, Viral, Human|HIV Infections, Behavioral: Testing, Education, & Counseling (TEC)|Behavioral: Hepatitis Care Coordination (HCC), Vaccination adherence visits|Health Care Utilization Survey|Intervention Costs & Hepatitis Care Utilization: DATCAP, public and private health care system administrative databases|Hepatitis A Knowledge Test|Hepatitis B Knowledge Test|Hepatitis C Knowledge Test|HIV Knowledge Test|Risk Behavior Survey|Addiction Severity Index, University of California, San Francisco|National Institute on Drug Abuse (NIDA), All, 18 Years and older   (Adult, Older Adult), Not Applicable, 489, Other|NIH, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research, R01DA020781, January 2008, June 2011, June 2011, February 6, 2008, , January 16, 2013, San Francisco General Hospital Opiate Treatment Outpatient Program, San Francisco, California, United States|Beth Israel Medical Center Methadone Maintenance Program, New York, New York, United States, , https://ClinicalTrials.gov/show/NCT00608192
1695, NCT00689546, Acute Viral Hepatitis and Diabetes Mellitus, , Unknown status, No Results Available, Acute Viral Hepatitis|Diabetes Mellitus, , Duration of icteric hepatitis.|Development of complications|Mortality, All India Institute of Medical Sciences, New Delhi, All, 18 Years to 70 Years   (Adult, Older Adult), , 250, Other, Observational, Observational Model: Case-Control|Time Perspective: Prospective, KKS-AVH-2008, February 2007, , , June 3, 2008, , June 3, 2008, All India Institute Of Medical Sciences, New Delhi, Delhi, India, , https://ClinicalTrials.gov/show/NCT00689546
1729, NCT01446978, Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs, , Unknown status, No Results Available, Vaccine Response Impaired, Biological: hepatitis A vaccine, seroconversion after the first dose/doses of hepatitis A vaccine|seroconversion rates after three doses of hepatitis A vaccine, Sormland County Council, Sweden, All, 18 Years and older   (Adult, Older Adult), Phase 2, 150, Other, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, Rombo - 2, September 2011, August 2016, August 2016, October 5, 2011, , November 18, 2015, Dept infectious diseases, Eskilstuna, Sweden|Department of infectious diseases, Stockholm, Sweden|Dept infectious diseases, Uppsala, Sweden|Dept infectious diseases, Örebro, Sweden, , https://ClinicalTrials.gov/show/NCT01446978
1745, NCT01756794, Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment, QuickTrans, Completed, No Results Available, Alcoholic Hepatitis|Alcoholic Cirrhosis, Procedure: Liver transplantation, Non-inferiority of alcohol relapse in early liver transplantation for severe alcoholic hepatitis as compared to patients transplanted for alcoholic cirrhosis.|Validation of the survival benefit of transplanted patients as compared to non-transplanted patients with severe alcoholic hepatitis|Reproducibility of an algorithm of selection for candidates to liver transplantation|Incidence of alcohol relapse|Pattern of alcohol relapse in the two groups of transplanted patients, University Hospital, Lille|Ministry of Health, France, All, 18 Years and older   (Adult, Older Adult), Not Applicable, 284, Other, Interventional, Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment, 2010-26|2012-A00088-35, December 5, 2012, June 7, 2018, December 5, 2019, December 27, 2012, , April 2, 2020, UZA, Anvers, Edegem, Belgium|ULB, Erasme, Bruxelles, Belgium|Gent, Belgium|Hospital Sart Tilman, Liege, Belgium|Univesity hospital, Amiens, France|University hospital, Angers, France|University hospital, Besançon, France|Hôpital Jean Verdier (AH-HP), Bondy, France|University hospital, Brest, France|University hospital, Caen, France|Univesity hospital, Chambray les tours, France|Hospital Antoine Béclère (Assistance Publique des Hôpiaux de Paris), Clamart, France|Hôpital Beaujon (AH-HP), Clichy, France|Hôpital Henri Mondor (AP-HP), Créteil, France|University hospital, Dijon, France|University hospital, Grenoble, France|University hospital, Lille, France|University hospital, Lyon, France|University Hospital, Montpellier, France|University hospital, Nancy, France|University hospital, Nantes, France|University hospital, Nice, France|Hôpital Saint Antoine (AP-HP), Paris, France|Hôpital de la Pitié-Salpétrière (AP-HP), Paris, France|Hôpital Cochin (AH-HP), Paris, France|University Hospital, Pessac, France|University hospital, Poitiers, France|University hospital, Reims, France|University hospital, Rennes, France|University Hospital, Strasbourg, France|University hospital, Toulouse, France|Hôpital Paul Brousse (AH-HP), Villejuif, France, , https://ClinicalTrials.gov/show/NCT01756794
1746, NCT04222803, VIRal Hepatitis and GAllstone Disease Study, VIRGAD, Not yet recruiting, No Results Available, Gallstone Attack|Viral Hepatitis, , Association between ongoing viral hepatitis (i.e. hepatitis A, B, C or E virus infection) and ultrasound or computed tomography-verified gallstone disease|Association between ongoing hepatitis A virus infection and ultrasound or computed tomography-verified gallstone disease|Association between ongoing hepatitis B virus infection and ultrasound or computed tomography-verified gallstone disease|Association between ongoing hepatitis C virus infection and ultrasound or computed tomography-verified gallstone disease|Association between ongoing hepatitis E virus infection and ultrasound or computed tomography-verified gallstone disease, Göteborg University, All, 18 Years to 100 Years   (Adult, Older Adult), , 350, Other, Observational, Observational Model: Case-Control|Time Perspective: Prospective, VIRGAD, January 15, 2020, January 15, 2021, June 1, 2021, January 10, 2020, , January 18, 2020, , , https://ClinicalTrials.gov/show/NCT04222803
1900, NCT04612634, Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine, , Recruiting, No Results Available, Vaccination, Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS, Antibody Seroconversion rate|Antibody Geometric Mean Titer (GMT)|Adverse Events Incidence rate, China National Biotec Group Company Limited|Changchun Institute of Biological Products Co., Ltd.|Shaanxi Provincial Center for Disease Control and Prevention|Mianxian Center for Disease Control and Prevention|Yangxian Center for Disease Control and Prevention|Peking University, All, 18 Months to 24 Months   (Child), Phase 4, 450, Industry|Other, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention, JGYM-2020-Ⅳ-01, November 2020, September 2021, November 2021, November 3, 2020, , November 3, 2020, Yangxian Center for Disease Control and Prevention, Hanzhong, Shaanxi, China|Mianxian Center for Disease Control and Prevention, Hanzhong, Shaanxi, China, , https://ClinicalTrials.gov/show/NCT04612634
1925, NCT02917577, Hepatitis A Vaccine Dosing Regimens Among Pediatric Rheumatology Patients on Immunosuppressive Therapy, , Recruiting, No Results Available, Autoimmune Rheumatologic Disease, Biological: Avaxim Pediatric®|Biological: Avaxim ® (adult), Hepatitis A antibodies titre, University of Calgary, All, 12 Years to 15 Years   (Child), Not Applicable, 60, Other, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention, HEP-2016, September 2016, December 2020, December 2020, September 28, 2016, , November 8, 2019, Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada, , https://ClinicalTrials.gov/show/NCT02917577
2035, NCT01914744, Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL, , Unknown status, No Results Available, Non-Hodgkin Lymphoma|Hepatitis B Reactivation, Drug: Entecavir|Drug: Lamivudine, Incidence rate of HBV reactivation|Incidence rate of hepatitis and HBV reactivation-related hepatitis|Incidence rate and median time of treatment delay due to hepatitis|Incidence rate and median time of HBV DNA level normalization, Fudan University, All, 18 Years to 80 Years   (Adult, Older Adult), Phase 2, 82, Other, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, LMTG 13-03, February 2013, December 2015, December 2016, August 2, 2013, , August 2, 2013, Fudan University Cancer Hospital, Shanghai, Shanghai, China, , https://ClinicalTrials.gov/show/NCT01914744
2087, NCT01310062, The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer, , Unknown status, No Results Available, Hepatitis B,Chronic|Carcinoma,Hepatocellular, , , Ministry of Health, Malaysia|GeneNews Sdn Bhd, All, 21 Years and older   (Adult, Older Adult), , 1600, Other, Observational, Time Perspective: Cross-Sectional, 09-317-3991, August 2010, , August 2012, March 7, 2011, , March 7, 2011, Sultanah Bahiyah Hospital, Alor Star, Kedah, Malaysia|Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia|Hospital Umum Kuching Sarawak, Kuching, Sarawak, Malaysia|Selayang Hospital, Selayang, Selangor, Malaysia|Kuala Lumpur Hospital, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Island Hospital, Pulau Pinang, Malaysia|Lam Wah Ee Hospital, Pulau Pinang, Malaysia|Penang Hospital, Pulau Pinang, Malaysia, , https://ClinicalTrials.gov/show/NCT01310062
2108, NCT02082639, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years, , Withdrawn, No Results Available, Infections, Papillomavirus, Biological: Cervarix™|Biological: Havrix, Anti-HPV-16/18 seroconversion status in the HPV group and the HPV+HAV group|Anti-HPV-16/18 antibody titres in the HPV group and the HPV+HAV group|Anti-HAV seroconversion status in the HPV+HAV group and the HAV group|Anti-HAV antibody titres in the HPV+HAV group and the HAV group|Occurrence of any and Grade 3 solicited local symptoms (injection site pain, redness and swelling) in all study groups|Occurrence of any, Grade 3 and causally related to vaccination solicited general symptoms in all study groups|Occurrence of any, Grade 3 and causally related to vaccination unsolicited AEs in all study groups|Occurrence of any and causally related to vaccination serious adverse events (SAEs) in all groups|Occurrence of medically significant conditions (MSCs) in all groups|Occurrence of potential immune-mediated diseases (pIMDs) in all groups|Occurrence of pregnancies and pregnancy outcomes, GlaxoSmithKline, Female, 9 Years to 14 Years   (Child), Phase 3, 0, Industry, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, 117099|2012-004378-24, February 2015, August 2015, November 2015, March 10, 2014, , July 20, 2015, , , https://ClinicalTrials.gov/show/NCT02082639
2150, NCT00155103, Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma, , Unknown status, No Results Available, Hepatitis B|Carcinoma, Hepatocellular|Polymorphism, Genetic, , , National Taiwan University Hospital|National Science Council, Taiwan, All, 18 Years and older   (Adult, Older Adult), , 1600, Other, Observational, Observational Model: Case-Control|Time Perspective: Retrospective, 9361700927|NSC 93-2314-B-002-226, August 2004, , , September 12, 2005, , March 21, 2007, Department of Medical Genetics; National Taiwan University Hospital, Taipei, Taiwan, , https://ClinicalTrials.gov/show/NCT00155103
2248, NCT01866072, Evaluation of Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure, ACLF, Unknown status, No Results Available, Acute Severe Viral Hepatitis|Acute on Chronic Liver Failure, , Fibroscan value at admission|Fibroscan value at week 1|Fibroscan value at week 4, Sir Ganga Ram Hospital, All, 18 Years to 70 Years   (Adult, Older Adult), , 100, Other, Observational, Observational Model: Case-Control|Time Perspective: Prospective, EC/01/13/455, May 2013, November 2013, January 2014, May 31, 2013, , June 4, 2013, Department of Gastroenterology & Hepatology, Sir Ganga Ram Hospital, New Delhi, India, , https://ClinicalTrials.gov/show/NCT01866072
2270, NCT03525119, Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine, , Completed, Has Results, Healthy Volunteers, Biological: TDV|Biological: HAV Vaccine|Biological: TDV Placebo|Biological: HAV Vaccine Placebo, Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30|Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 30 and Day 120 in Participants HAV/DENV-naive at Baseline|Percentage of Participants HAV/DENV-naive at Baseline Who Are Seropositive for Each of the 4 Dengue Serotypes at Day 30 and Day 120|Geometric Mean Concentrations (GMC) of Anti-HAV Antibodies at Day 30 in Participants HAV/DENV-naive at Baseline|Percentage of Participants With Solicited (Local Injection) Site Adverse Events (AEs) by Severity After Each Vaccination|Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination|Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination|Percentage of Participants With Serious Adverse Events (SAEs)|Percentage of Participants With Medically Attended AEs (MAAEs), Takeda, All, 18 Years to 60 Years   (Adult), Phase 3, 900, Industry, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention, DEN-314|2017-001071-23|U1111-1192-7761|18/NW/0008, May 16, 2018, October 3, 2018, July 9, 2019, May 15, 2018, July 13, 2020, July 13, 2020, Synexus - Midlands, Edgbaston, Birmingham, United Kingdom|Synexus - Lancashire, Chorley, Lancashire, United Kingdom|Synexus - Merseyside, Waterloo, Liverpool, United Kingdom|Royal Hallamshire Hospital, Sheffield, Yorkshire, United Kingdom|Synexus - Wales, Cardiff, United Kingdom|Synexus - Scotland, Glasgow, United Kingdom|North East Clinical Research Centre, Hexham General Hospital, Hexham, United Kingdom|Synexus - Manchester, Manchester, United Kingdom|Synexus - Thames Valley, Reading, United Kingdom|North Tees Clinical Research Centre, Middlefield Centre, University Hospital of North Tees, Stockton-on-Tees, United Kingdom, "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03525119/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03525119/SAP_001.pdf, https://ClinicalTrials.gov/show/NCT03525119
2428, NCT04106518, Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease, COMADHAA, Recruiting, No Results Available, Alcoholic Liver Disease|Severe Alcoholic Hepatitis|Alcoholic Cirrhosis, , Prevalence of alcoholic hepatitis in heavy drinkers with jaundice|Survival|Change in serum total bilirubin|Change in serum creatinine|Change in MELD (Model for End-stage Liver Disease)score|Identification of inflammatory and biochemical profiles of patients with severe, non-severe and cirrhotic alcoholic hepatitis, based on the constitution of a biobank (serum and plasma)|Identification of the genetic profiles of individuals with severe, non-severe and cirrhotic alcoholic hepatitis( blood sample)|Measurement of diagnostic performance (area under the ROC curve), University Hospital, Lille, All, 18 Years and older   (Adult, Older Adult), , 447, Other, Observational, Observational Model: Cohort|Time Perspective: Prospective, 2017_51|2018-A02286-49, October 23, 2019, October 2022, October 2022, September 27, 2019, , November 18, 2020, Chru Besancon, Besançon, France|Hôpital Jean Verdier, AH-HP, Bondy, France|Centre Hospitalier Universitaire, Caen, France|Hôpital Claude Huriez, CHU, Lille, France|Chu Montpellier, Montpellier, France, , https://ClinicalTrials.gov/show/NCT04106518
2504, NCT00598416, Psychoeducation for Hepatitis and Alcohol Behaviors, , Completed, No Results Available, Hepatitis C|Substance Abuse, Behavioral: Family-Responsive Psychoeducation Program (PERF), Increased treatment readiness and better treatment adherence for treatment of HCV.|Better management of substance abuse and other psychiatric disorders.|Better social functioning and increased quality of life., National Institute on Alcohol Abuse and Alcoholism (NIAAA), All, 18 Years and older   (Adult, Older Adult), Not Applicable, 556, NIH, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care, NIAAA-NORTH-AA015201|R01AA015201, September 2006, August 2013, August 2013, January 21, 2008, , November 4, 2014, Washington University School of Medicine, St. Louis, Missouri, United States, , https://ClinicalTrials.gov/show/NCT00598416
2570, NCT02375867, Steroids in Fulminant Hepatitis A in the Pediatric Age Group, , Completed, No Results Available, Fulminant Hepatic Failure, Drug: prednisolone|Drug: methylprednisolone, Side effect 1 Number of patients with anaphylaxis|Side effect 2 Number of patients with angioedema|Side effect 3 Number of patients with cardiac arrest|Side effect 4 Number of patients with arrhythmias|Side effect 5 Number of patients with circulatory collapse|Side effect 6 Number of patients with congestive heart failure|Side effect 7 Number of patients with pulmonary edema|Side effect 8 Number of patients with pancreatitis|Efficacy 1 Number of survivors|Efficacy 2 Number of deaths|Efficacy 3 serum prothrombin time|Efficacy 3 grade of encephalopathy|Efficacy 4 duration of encephalopathy, National Liver Institute, Egypt|Quesna Central Hospital, Ministry Of Health, Egypt, All, up to 18 Years   (Child, Adult), Phase 4, 33, Other, Interventional, Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment, NLI-FHF-S-PED, January 2015, August 2017, September 2017, March 3, 2015, , December 17, 2018, National Liver Institute, Menoufia, Egypt, "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02375867/Prot_SAP_001.pdf, https://ClinicalTrials.gov/show/NCT02375867
2634, NCT02588560, Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy, , Unknown status, No Results Available, Lymphoma|Hepatitis C Antibodies|Drug Therapy, , Number of Participants with Increasing HCV RNA Level and Developing Hepatitis after Chemotherapy|Number of Participants with Detectable Viremia and Developing Hepatitis after Chemotherapy|Interval (months) between Peak HCV RNA Level and Hepatitis|Increase (log) of HCV Viral Load between Baseline and after Chemotherapy|Number of Participants with Hepatitis after Chemotherapy|Number of Participants with Severe Hepatitis after Chemotherapy|Number of Participants with Chemotherapy Interruption due to Hepatotoxicity|Number of Participants with Early Stop of Chemotherapy due to Hepatotoxicity, Chang Gung Memorial Hospital, All, 20 Years and older   (Adult, Older Adult), , 38, Other, Observational, Observational Model: Case-Only|Time Perspective: Prospective, 103-7486B, September 2015, August 2019, August 2019, October 28, 2015, , October 28, 2015, , , https://ClinicalTrials.gov/show/NCT02588560
2673, NCT02907905, Epidemiology of Viral Hepatitis Among Subjects in Precarious, , Recruiting, No Results Available, Social Insecurity, Biological: capillary sampling, serology HBV|serology HCV|serology HAV, University Hospital, Montpellier, All, 18 Years to 100 Years   (Adult, Older Adult), Not Applicable, 200, Other, Interventional, Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic, 9609, March 1, 2016, November 1, 2019, December 1, 2019, September 20, 2016, , August 7, 2019, DUCOS, Montpellier, France, , https://ClinicalTrials.gov/show/NCT02907905
2937, NCT00216229, Twinrix Alternative Schedule Study, , Unknown status, No Results Available, Antibody Response After Vaccination, Biological: Combined vaccine against hepatitis A and B (Twinrix), Anti-HBs antibodies concentration 1 month after 3th vaccine dose|Natural evolution of anti-HBs antibodies concentration between 2nd and 3th vaccine dose (5-11 months), IDEWE Occupational Health Services|GlaxoSmithKline, All, 18 Years and older   (Adult, Older Adult), Phase 4, 400, Other|Industry, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, IDEWE-301|04-033, September 2004, , February 2006, September 22, 2005, , December 14, 2005, IDEWE, Leuven, Belgium, , https://ClinicalTrials.gov/show/NCT00216229
3085, NCT01528280, Humoral and Cellular Response in Shift Workers, , Completed, No Results Available, Other Condition That May be a Focus of Clinical Attention, Biological: Vaccination against hepatitis A|Other: No Intervention, Antibodies against hepatitis A virus (anti-HAV)|Intracellular cytokines|Catecholamines|Prolactin|Growth hormone|Cortisol|Sleep disorders, Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo, Male, 18 Years to 55 Years   (Adult), Not Applicable, 34, Other, Interventional, Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science, CEPE2012FRuiz, January 2013, September 2014, December 2016, February 8, 2012, , January 11, 2018, Centro de Estudos em Psicobiologia e Exercicio _ CEPE, Sao Paulo, SP, Brazil|Centro de Estudos em Psicobiologia e Exercicio - CEPE, Sao Paulo, Brazil, , https://ClinicalTrials.gov/show/NCT01528280
3420, NCT00393276, Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals, , Completed, No Results Available, HIV Infections|Hepatitis C, Biological: Twinrix|Biological: Decavac, B-cell humoral responses|T-cell responses as reflected by hepatitis B and tetanus antibody titers|Dendritic cell, B-cell, and T-cell functional markers|B-cell functional marker|T-cell responses to hepatitis A, hepatitis B, and tetanus antigens|Longitudinal serum antibody titers to hepatitis A, hepatitis B, and tetanus (B-cell responses)|CD4/CD8 and HCV genotype|Baseline antibody status for hepatitis B core antigen (anti-HBc), National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group, All, 18 Years to 65 Years   (Adult, Older Adult), Phase 1, 29, NIH|Other, Interventional, Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, A5232|10154|1R21AI066957-01|ACTG A5232, August 2007, July 2009, July 2009, October 27, 2006, , December 9, 2014, UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Aids Crs, San Francisco, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|IHV Baltimore Treatment CRS, Baltimore, Maryland, United States|Massachusetts General Hospital Clinical Research Site (MGH CRS) CRS, Boston, Massachusetts, United States|Columbia P&S CRS, New York, New York, United States|Duke Univ. Med. Ctr. Adult CRS, Durham, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|MetroHealth CRS, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico, , https://ClinicalTrials.gov/show/NCT00393276
3496, NCT00005304, Delta Hepatitis and Liver Disease in Hemophiliacs, , Completed, No Results Available, Blood Disease|Hepatitis, Viral, Human|Hemophilia A|Liver Diseases, , , Baylor College of Medicine|National Heart, Lung, and Blood Institute (NHLBI), Male, up to 100 Years   (Child, Adult, Older Adult), , , Other|NIH, Observational, , 3005|R01HL037951, September 1986, , September 1991, May 26, 2000, , April 7, 2020, , , https://ClinicalTrials.gov/show/NCT00005304
3550, NCT00688389, Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection, , Unknown status, No Results Available, Dengue Fever, Other: case/control, 檢查肝臟、腎臟及其他生化功能，並分析宿主免疫調控及血小板變化機致, Kaohsiung Medical University Chung-Ho Memorial Hospital|Centers for Disease Control and Prevention, All, Child, Adult, Older Adult, , 700, Other|U.S. Fed, Observational, Observational Model: Case-Control|Time Perspective: Other, KMUH-IRB-960195_1|CB9615, July 2007, December 31, 2020, December 31, 2020, June 2, 2008, , February 28, 2019, Kaoshing Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan, , https://ClinicalTrials.gov/show/NCT00688389
3620, NCT04268173, Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3, , Suspended, No Results Available, Drug Use Disorders|Hepatitis C|Harm Reduction|Opioid-use Disorder, Other: Community-Based, Client-Centered Prevention Home, Change in the addiction treatment accessibility and utilization as assessed by change in Likert scale|Change in the addiction treatment accessibility and utilization as assessed by change in frequency of "Yes" answers|Change in the risk of viral hepatitis as assessed by change in Likert scale|Change in the risk of HIV as assessed by change in Likert scale|Change in the risk of HIV as assessed by risky behavior frequencies|Change in the risk of drug overdose as assessed by change in Likert scale|Change in smoking frequency as assessed by self-reported behaviors|Change in Self-stigma as assessed by change in Likert scale|Change in the risk of drug overdose as assessed by change in frequency of narcan distribution|Change in the treatment frequency of viral hepatitis as assessed by Wisconsin(WI) surveillance databases and Medicaid data., University of Wisconsin, Madison|Tulane University|National Institute on Drug Abuse (NIDA), All, 18 Years and older   (Adult, Older Adult), Phase 3, 500, Other|NIH, Interventional, Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research, 2017-0866|UH3DA044826|A534265|SMPH/MEDICINE/INFECT DIS, March 12, 2020, July 31, 2022, July 31, 2022, February 13, 2020, , June 2, 2020, Vivent Health, Appleton, Wisconsin, United States|Vivent Health, Eau Claire, Wisconsin, United States|Vivent Health, Green Bay, Wisconsin, United States|Vivent Health, La Crosse, Wisconsin, United States|University of Wisconsin, Madison, Madison, Wisconsin, United States|Vivent Health, Schofield, Wisconsin, United States|Vivent Health, Superior, Wisconsin, United States, , https://ClinicalTrials.gov/show/NCT04268173
3686, NCT01947465, Immunogenicity and Safety of Vaccinations in Immunocompromised Persons, , Completed, No Results Available, Arthritis, Rheumatoid|Spondylarthritis|Vasculitis, Biological: Hepatitis A vaccine and tetanus vaccine, Immunogenicity of hepatitis A and tetanus vaccination in patients with rheumatoid arthritis, axial spondyloarthritis and vasculitis and in healthy controls|Safety of tetanus and hepatitis A vaccines in patients with rheumatoid arthritis, axial spondyloarthritis and vasculitis and in healthy controls, University of Zurich|University of Basel|Swiss Tropical & Public Health Institute|University of Bern|University Hospital, Geneva|Cantonal Hospital of St. Gallen|Cantonal Hospital of Aarau, Switzerland, All, 18 Years and older   (Adult, Older Adult), , 645, Other, Observational, Observational Model: Cohort|Time Perspective: Prospective, CS_2013_01, October 2013, December 2015, February 2016, September 20, 2013, , February 25, 2016, Cantonal Hospital Aarau, Division of Rheumatology, Aarau, Aargau, Switzerland|University Hospital of Basel, Rheumatology Division, Basel, Basel Town, Switzerland|Swiss Tropical and Public Health Institute, Basel, Basel Town, Switzerland|University of Bern, Inselspital, Division of Infectious Diseases and Travel Medicine, Bern, Switzerland|University of Bern, Inselspital, Division of Rheumatology, Bern, Switzerland|University of Geneva, University Hospitals, Division of Rheumatology, Geneva, Switzerland|University of Geneva, University Hospitals, Service de Médecine Tropicale et Humanitaire, Geneva, Switzerland|Cantonal Hospital St. Gallen, Division of Rheumatology, St. Gallen, Switzerland|University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Divison of Infectious Diseases, Zürich, Switzerland|University of Zurich, University Hopsital, Divison of Rheumatology, Zürich, Switzerland, , https://ClinicalTrials.gov/show/NCT01947465
3690, NCT00578175, Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age, , Completed, Has Results, Varicella|Rubella|Mumps|Measles, Biological: Priorix-Tetra™ (MMRV vaccine 208136)|Biological: ProQuad®|Biological: Havrix®|Biological: Prevnar®, Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV)|Concentration of Antibodies to Varicella Virus (VZV)|Number of Subjects With Seroresponse for Antibodies to Mumps Virus|Number of Subjects With Seroresponse for Antibodies to Measles Virus|Number of Subjects With Seroresponse for Antibodies to Rubella Virus|Concentration of Antibodies to Hepatitis A Virus (HAV)|Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F|Antibody Titers to Mumps Virus|Concentration of Antibodies to Measles Virus|Concentration of Antibodies to Rubella Virus|Number of Subjects With Vaccine Response to Havrix|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Fever ≥ 38.0°C/100.4°F and > 39.5°C/103.1°F During the 15-day Follow up Period After Vaccination|Number of Subjects Reporting Fever ≥ 38.0°C/100.4°F and > 39.5°C/103.1°F During the 43-day Follow-up Period After Vaccination|Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash|Number of Subjects Reporting Investigator-confirmed Varicella-like Rash|Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling|Number of Subjects Reporting Unsolicited Adverse Events and Medically-attended Adverse Events (Excluding Rash and Parotid/Salivary Gland Swelling)|Number of Subjects Reporting New Onset Chronic Illnesses and Conditions Prompting Emergency Room Visits|Number of Subjects Reporting Serious Adverse Events, GlaxoSmithKline, All, 12 Months to 14 Months   (Child), Phase 2, 1851, Industry, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention, 110058, November 20, 2007, February 24, 2009, March 17, 2009, December 21, 2007, August 26, 2010, October 9, 2018, GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Tuscaloosa, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Benton, Arkansas, United States|GSK Investigational Site, Jonesboro, Arkansas, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Buena Park, California, United States|GSK Investigational Site, Downey, California, United States|GSK Investigational Site, Fountain Valley, California, United States|GSK Investigational Site, Fremont, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Hayward, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Lakewood, California, United States|GSK Investigational Site, Oakland, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, Pleasanton, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Vacaville, California, United States|GSK Investigational Site, West Covina, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Thornton, Colorado, United States|GSK Investigational Site, Westminster, Colorado, United States|GSK Investigational Site, Boynton Beach, Florida, United States|GSK Investigational Site, Opa-locka, Florida, United States|GSK Investigational Site, Plantation, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Carrollton, Georgia, United States|GSK Investigational Site, Dalton, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Tifton, Georgia, United States|GSK Investigational Site, Tucker, Georgia, United States|GSK Investigational Site, Woodstock, Georgia, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Nampa, Idaho, United States|GSK Investigational Site, DeKalb, Illinois, United States|GSK Investigational Site, Fishers, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, New Albany, Indiana, United States|GSK Investigational Site, Dubuque, Iowa, United States|GSK Investigational Site, Dubuque, Iowa, United States|GSK Investigational Site, Waukee, Iowa, United States|GSK Investigational Site, West Des Moines, Iowa, United States|GSK Investigational Site, Arkansas City, Kansas, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Topeka, Kansas, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Bardstown, Kentucky, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Springfield, Kentucky, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Frederick, Maryland, United States|GSK Investigational Site, Fall River, Massachusetts, United States|GSK Investigational Site, Woburn, Massachusetts, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Niles, Michigan, United States|GSK Investigational Site, Portage, Michigan, United States|GSK Investigational Site, Richland, Michigan, United States|GSK Investigational Site, Stevensville, Michigan, United States|GSK Investigational Site, Brainerd, Minnesota, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Bridgeton, Missouri, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, White House Station, New Jersey, United States|GSK Investigational Site, Johnson City, New York, United States|GSK Investigational Site, Lake Success, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Stony Brook, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Boone, North Carolina, United States|GSK Investigational Site, Cary, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Sylva, North Carolina, United States|GSK Investigational Site, Fargo, North Dakota, United States|GSK Investigational Site, Minot, North Dakota, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Fairfield, Ohio, United States|GSK Investigational Site, Huber Heights, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Gresham, Oregon, United States|GSK Investigational Site, Altoona, Pennsylvania, United States|GSK Investigational Site, East Norriton, Pennsylvania, United States|GSK Investigational Site, Kittanning, Pennsylvania, United States|GSK Investigational Site, Latrobe, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Sellersville, Pennsylvania, United States|GSK Investigational Site, Uniontown, Pennsylvania, United States|GSK Investigational Site, Wexford, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Brentwood, Tennessee, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Amarillo, Texas, United States|GSK Investigational Site, Bryan, Texas, United States|GSK Investigational Site, Corpus Christi, Texas, United States|GSK Investigational Site, Lubbock, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Sugar Land, Texas, United States|GSK Investigational Site, Layton, Utah, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Provo, Utah, United States|GSK Investigational Site, Saint George, Utah, United States|GSK Investigational Site, South Jordan, Utah, United States|GSK Investigational Site, West Jordan, Utah, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Chesapeake, Virginia, United States|GSK Investigational Site, Midlothian, Virginia, United States|GSK Investigational Site, Vienna, Virginia, United States|GSK Investigational Site, Virginia Beach, Virginia, United States|GSK Investigational Site, Huntington, West Virginia, United States|GSK Investigational Site, La Crosse, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Marshfield, Wisconsin, United States, , https://ClinicalTrials.gov/show/NCT00578175
3700, NCT00861744, Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age, , Completed, Has Results, Rubella|Mumps|Measles|Measles-Mumps-Rubella Vaccine, Biological: GSK Biological's investigational vaccine 209762|Biological: M-M-R® II (Merck and Co)|Biological: Varivax®|Biological: Havrix®|Biological: Prevnar®, Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value.|Number of Subjects With Anti-mumps Virus Antibody Titer Equal to or Above the Cut-off-value.|Number of Subjects With Anti-rubella Virus Antibody Concentrations Equal to or Above the Cut-off-value.|Number of Subjects With Anti-varicella Antibody Concentration Equal to or Above the Cut-off-value.|Anti-measles Virus Antibody Concentrations|Anti-mumps Virus Antibody Concentrations|Anti-rubella Virus Antibody Concentrations|Anti-S. Pneumoniae Antibody Concentrations (by Serotype).|Anti-varicella Antibody Concentrations.|Anti-hepatitis A Virus Antibody Concentrations.|Number of Subjects With Anti-hepatitis A Antibody Concentrations Equal to or Above the Cut-off-value.|Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value|Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash and Varicella-like Rash.|Number of Subjects Reporting Febrile Convulsions|Anti-mumps Virus Antibody Titers (Enhanced Plaque Reduction Neutralization (PRN))|Number of Subjects Reporting Other Rash.|Number of Subjects With Anti-mumps Virus Antibody Titers Above the Cut-off Value (Enhanced PRN)|Number of Subjects Reporting Fever.|Number of Subjects With Solicited Local Symptoms.|Number of Subjects Reporting Medically Attended Visit (MAEs)|Number of Subjects With Unsolicited Adverse Events (AEs).|Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling.|Number of Subjects With Solicited General Symptoms.|Number of Subjects Reporting New Onset Chronic Illnesses (NOCIs).|Number of Subjects Reporting Serious Adverse Events (SAEs)|Number of Subjects Reporting Serious Adverse Events (SAEs).|Number of Subjects Reporting Conditions Prompting Emergency Room (ER) Visits.|Anti-mumps Virus Antibody Titers (Unenhanced PRN)|Number of Subjects With Anti-mumps Virus Antibody Titers Above the Cut-off Value (Unenhanced PRN)|Anti-mumps Virus Antibody Concentrations (Pharmaceutical Product Development (PPD) ELISA)|Number of Subjects With Anti-mumps Virus Antibody Concentrations Above the Cut-off Value (PPD ELISA)|Anti-mumps Virus Antibody Concentrations (PPD ELISA), GlaxoSmithKline, All, 12 Months to 15 Months   (Child), Phase 2, 1259, Industry, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention, 111870|2011-005860-31, June 3, 2009, July 21, 2010, June 18, 2012, March 13, 2009, November 4, 2011, January 3, 2020, GSK Investigational Site, Tuscaloosa, Alabama, United States|GSK Investigational Site, Conway, Arkansas, United States|GSK Investigational Site, Jonesboro, Arkansas, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Downey, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, Santa Ana, California, United States|GSK Investigational Site, West Covina, California, United States|GSK Investigational Site, Altamonte Springs, Florida, United States|GSK Investigational Site, Dalton, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Nampa, Idaho, United States|GSK Investigational Site, DeKalb, Illinois, United States|GSK Investigational Site, Arkansas City, Kansas, United States|GSK Investigational Site, Bardstown, Kentucky, United States|GSK Investigational Site, Bossier City, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Fall River, Massachusetts, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Great Falls, Montana, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Cary, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Gresham, Oregon, United States|GSK Investigational Site, East Norriton, Pennsylvania, United States|GSK Investigational Site, Rydal, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Corpus Christi, Texas, United States|GSK Investigational Site, Layton, Utah, United States|GSK Investigational Site, Provo, Utah, United States|GSK Investigational Site, Saint George, Utah, United States|GSK Investigational Site, Springville, Utah, United States|GSK Investigational Site, West Jordan, Utah, United States|GSK Investigational Site, Virginia Beach, Virginia, United States|GSK Investigational Site, Huntington, West Virginia, United States|GSK Investigational Site, Bayamon, Puerto Rico|GSK Investigational Site, San Germán, Puerto Rico|GSK Investigational Site, San Juan, Puerto Rico, , https://ClinicalTrials.gov/show/NCT00861744
3963, NCT00001078, A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications, , Completed, No Results Available, HIV Infections, Biological: Hepatitis A Vaccine (Inactivated), , National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), All, 2 Years to 21 Years   (Child, Adult), Not Applicable, 200, NIH, Interventional, Primary Purpose: Treatment, ACTG P1008|PACTG P1008, , May 2005, , August 31, 2001, , March 2, 2011, Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Phoenix Childrens Hosp, Phoenix, Arizona, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Children's Hosp of Oakland, Oakland, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Yale Univ Med School, New Haven, Connecticut, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Palm Beach County Health Dept, Riviera Beach, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Cook County Hosp, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|UMDNJ - Robert Wood Johnson Med School / Pediatrics, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|SUNY - Brooklyn, Brooklyn, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Columbus Children's Hosp, Columbus, Ohio, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Med College of Virginia, Richmond, Virginia, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico, , https://ClinicalTrials.gov/show/NCT00001078
4021, NCT02526550, Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX, , Completed, Has Results, Encephalitis, Biological: Live attenuated chimeric Japanese Encephalitis vaccine|Biological: Inactivated Hepatitis A vaccine, Change From Baseline in Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus at 28 Days Post Vaccination|Change From Baseline in Number of Participants With Seroprotection Against Japanese Encephalitis Chimeric Virus at 28 Days Post Vaccination|Percentage of Number of Participants Reporting Immediate Reactions, Solicited Injection Site and Systemic Reactions, Unsolicited Adverse Events, and Serious Adverse Events Following Vaccination With IMOJEV™, Siriraj Hospital|Sanofi Pasteur, a Sanofi Company, All, 1 Year to 5 Years   (Child), Phase 4, 50, Other|Industry, Interventional, Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention, JEC26-EXT, June 2014, July 2014, July 2014, August 18, 2015, December 7, 2016, December 7, 2016, , , https://ClinicalTrials.gov/show/NCT02526550
4023, NCT00031070, Increasing HAART-Induced Immune Restoration With Cyclosporine, , Completed, No Results Available, HIV Infections, Drug: Abacavir sulfate, Lamivudine and Zidovudine|Drug: Cyclosporine|Biological: Hepatitis A Vaccine (Inactivated)|Drug: Efavirenz|Biological: Pneumococcal Conjugate Vaccine, Heptavalent|Biological: Rabies Vaccine, , National Institute of Allergy and Infectious Diseases (NIAID), All, 18 Years and older   (Adult, Older Adult), Phase 2, 40, NIH, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment, ACTG A5138|AACTG A5138|ACTG A5139s|AACTG A5139s, , , December 2006, February 22, 2002, , March 9, 2015, University of California , Davis Medical Center, Sacramento, California, United States|University of Miami, Miami, Florida, United States|Rush Presbyterian - Saint Luke's Med Ctr / Infect Dis, Chicago, Illinois, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|Univ of Minnesota, Minneapolis, Minnesota, United States|Washington Univ (St. Louis), St. Louis, Missouri, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Univ of North Carolina / Infectious Disease Division, Chapel Hill, North Carolina, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States|Univ of Texas Southwestern Med Ctr, Dallas, Texas, United States|Univ of Texas, Southwestern Med Ctr of Dallas, Dallas, Texas, United States, , https://ClinicalTrials.gov/show/NCT00031070
4027, NCT00004735, The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV, , Completed, No Results Available, HIV Infections, Biological: Tetanus toxoid|Biological: Hepatitis A Vaccine (Inactivated), A stimulation index of 3 or greater on at least 2 occasions to tetanus|positive serologic response to hepatitis A|four-fold increase over baseline in antibody titers for tetanus|A stimulation index of 3 or greater on at least 2 occasions to hepatitis A and Candida|increase in CD4 cell percentage by 10% and absolute CD4 number by 150 cells/ml|development of any adverse events of Grade 3 or higher attributable to vaccination, National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), All, 2 Years to 24 Years   (Child, Adult), Not Applicable, 81, NIH, Interventional, Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment, PACTG P1006|10036, February 2000, , September 2006, August 31, 2001, , October 7, 2013, UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Usc La Nichd Crs, Alhambra, California, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Children's National Med. Ctr., ACTU, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Schneider Children's Hosp., Div. of Infectious Diseases, New Hyde Park, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|UW School of Medicine - CHRMC, Seattle, Washington, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico, , https://ClinicalTrials.gov/show/NCT00004735